EF Consulting- Announces the Sale of the Holistic Breast Patch Patent

LOS ANGELES - Oct. 7, 2015 - PRLog -- Los Angeles, California October 7, 2015: EF Consulting representing B-Win Enterprise, announces the exclusive offer to purchase the Holistic Breast Patch (HBP) patent. U.S. Patent No.: 8,562,575 B2. B-Win Enterprise, objective is to sell U.S. patent rights to a pharmaceutical company and/or investor, with an interest in an over- the- counter (OTC), self-administered patent; intended for commercialized use.

EF Consulting representing B-Win Enterprise announced today the exclusive offer to purchase the Holistic Breast Patch patent. This Intellectual Property (IP) belongs to product developer and patent owner Samuel E. Baldwin, doing business as B-Win Enterprise. B-Win Enterprise developed the HBP to aid in the suppression of breast milk production and relieve breast engorgement pain, women experience after childbirth.

According to data from the National Vital Statistics Report, in 2013- 3,957,577 infants were born in the United States. However, lactation suppression is the forgotten aspect of women postpartum care. The most recent report from the State of the World’s Mothers Report stated, the United States ranks last on the Breastfeeding Policy Scorecard.A variety of issues and concerns may prevent a mother from breastfeeding, some of these challenges includes, but not limited to: stillbirth, adoption, employment, health reasons, etc.  Currently, there is no drug approved by the Food Drug Administration (FDA), to safely provide relief from breast engorgement pain and/or breast milk suppression.

About the Holistic Breast Patch Device
The HBP is the first known drug-free all natural, and effective, apparatus available, that safely inhibits prolactin production and aids the relief of discomfort from breast engorgement pain. The HBP target audience are postpartum women who elects not to breastfeed and/or women who desires to discontinue breastfeeding. After pregnancy a, woman naturally produces breast milk for a period of time. However, there is not Federal Drug Administration (FDA) approved treatment for breast milk suppression or breast engorgement pain. The FDA has determined the HBP as a device not a drug, and meets the definition of a non-significant risk device (21 CFR 812).  For more information about the HBP, please visit: www.holisticbreastpatch.com

About EF Consulting
EF Consulting is headquartered in Pasadena, CA, and since 2013 has specialized in providing business solutions for corporate businesses’ and nonprofit organizations. EF Consulting is skilled at guiding entities on best practices and long-term strategic growth.

https://www.youtube.com/watch?v=B6RE-6pAuWg